Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant / Intolerant Ph + Chronic Myeloid Leukemia",
Multiple Cancer Types
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R / I CML), to preliminary estimate the safety and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient population.
Pediatric Leukemia, Pediatrics